Category: Joint ventures/collaborations
-
Biopharm, Hospital to Partner on Cell Energy Diseases
A biopharmaceutical company in Sweden and children’s hospital in the U.S. are collaborating on research into deficiencies in cells’ energy components responsible for a number of genetic disorders.
-
UC San Francisco, Intel Partner on Health Analytics
Intel Corporation and University of California in San Francisco are developing a data analytics platform that harnesses artificial intelligence to help front-line clinicians make better decisions for their patients.
-
Pharma Firms Start Non-Communicable Disease Initiative
A group of 22 pharmaceutical companies is supporting worldwide projects to improve access to prevention and treatments for chronic disorders like cancer and heart disease, in lower-resource regions.
-
Electronic Gene Editing Corrects Inherited Blood Disorder
A team at National Institutes of Health used an electronic-aided process to carry out a gene editing technique that in lab mice repaired a genetic defect causing a rare blood disease.
-
MD Anderson, Investment Firm Create Cancer Start-Up
MD Anderson Cancer Center and health care investment enterprise Deerfield Management are starting a new company to develop treatments for cancer that tackle processes feeding tumor growth.
-
Scripps, Pfizer Collaborate on DNA-Coded Drug Discovery
Drug maker Pfizer Inc. is gaining access to advances in a synthetic chemistry technology developed by Scripps Research Institute that tags compounds with DNA identifiers.
-
Illumina Partnering with IBM, Phillips on Genomics Tools
Genomics technology company Illumina Inc. is collaborating with technology enterprises IBM and Royal Phillips to expand its sequencing services in precision medicine for cancer.
-
Sanofi Licensing Antibody for Autoimmune Diseases
The global drug company Sanofi is licensing a synthetic antibody to treat autoimmune disorders being developed by a spin-off enterprise from Dartmouth College.
-
Ionis Options Cardiac Drugs in $1.5 Billion Deal
Biotechnology company Ionis Pharmaceuticals is providing drug maker Novartis first access to two experimental drugs for controlling proteins that promote cholesterol and triglycerides, which contribute to heart disease.
-
Precision Health Tech Network Expands, Invests $400M
Digital Life Alliance, a consortium of enterprises applying advanced technologies to health and medicine that plans to offer personalized solutions, is expanding to 7 members, as well as iCarbonX, the company that founded the network.